NBY News and Press, NovaBay Pharmaceuticals Inc. From 11/07/19

NovaBay (NYSEMKT: NBY ): Q3 GAAP EPS of -$0.02 beats by $0.06 . More news on: NovaBay Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Conference call begins at 4:30 p.m. Eastern time today NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, reports financial results for the three and nine months ended...

Prescription-strength CelleRx to gently clean skin and ease post-procedure discomfort is now available without a prescription at www.CelleRx.com NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces the availability of full-strength CelleRx for consumer purchase with...

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that it will report third quarter 2019 financial results after market close on Thursday, November 7, 2019 and will ...

Once-daily system complements Avenova and leverages salesforce calls on eyecare specialists NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces an exclusive 90-...

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that it has received approval for the distribution of Avenova from the Australian Government Department of Health a...

Axsome Therapeutics (NASDAQ: AXSM ) initiated with Outperform rating at William Blair. Shares up  1%  premarket. More news on: Axsome Therapeutics, Inc., Canopy Growth Corporation, Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that Yenyou (Jeff) Zheng, Ph.D. has joined the Company’s board as an independent director. Dr. Zheng will ch...

NovaBay ® Pharmaceuticals, Inc . (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that management will present at two upcoming investment conferences: RHK Capital 4 th Annual Disruptive Growth C...

NovaBay Pharmaceuticals ( NBY -14.8% ) is down on below-average volume on the heels of its agreement to sell ~4.2M common shares and accompanying unregistered five-year warrants to purchase up to the same number of shares at $1.15 to institutional investors at $1 per share and warrant. C...